|Videos|June 12, 2019

Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Related Content

3 Things You Should Know About Targeted Therapies for Gliomas

TRIDENT Trial Finds No Survival Benefit With Earlier Tumor Treating Fields Use

NCCN Expands CSF Molecular Profiling Recommendation to Inoperable High-Grade Glioma

FDA Clears Alpha DaRT Trial to Complete Enrollment in Recurrent GBM

Radiation Oncology Trials You May Have Missed at ASCO 2026

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Kansas Society of Clinical Oncology

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

25th Annual International Congress on the Future of Breast Cancer® West

25th Annual International Congress on the Future of Breast Cancer® East

Arizona Clinical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Indiana Oncology Society

Arkansas Association of Cancer Professionals

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Washington State Medical Oncology Society

Colorado Oncology Society

27th Annual International Lung Cancer Congress®

Satellite Symposia at the Annual Radiation Oncology Meeting

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

North Carolina Oncology Association

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Diagnosis and Management of TGCT

Optimizing Multidisciplinary Care in TGCT

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology